Service de Rhumatologie, Cochin Hospital, APHP, Paris Descartes University, 27 rue du Faubourg Saint Jacques, 75014, Paris, France.
Sanofi R&D, Chilly-Mazarin, France.
Arthritis Res Ther. 2020 Oct 28;22(1):257. doi: 10.1186/s13075-020-02329-2.
Patients with diffuse cutaneous systemic sclerosis (dcSSc) have a poor prognosis. The importance of monitoring subjective measures of functioning and disability, such as the Health Assessment Questionnaire-Disability Index (HAQ-DI), is important as dcSSc is rated by patients as worse than diabetes or hemodialysis for quality of life impairment. This European Scleroderma Trials and Research (EUSTAR) database analysis was undertaken to examine the importance of impaired functionality in dcSSc prognosis. The primary objectives were to identify predictors of death and HAQ-DI score progression over 1 year. HAQ-DI score, major advanced organ involvement, and death rate were also used to develop a comprehensive model to predict lifetime dcSSc progression.
This was an observational, longitudinal study in patients with dcSSc registered in EUSTAR. Death and HAQ-DI scores were, respectively, analyzed by Cox regression and linear regression analyses in relation to baseline covariates. A microsimulation Markov model was developed to estimate/predict natural progression of dcSSc over a patient's lifetime.
The analysis included dcSSc patients with (N = 690) and without (N = 4132) HAQ-DI score assessments from the EUSTAR database. Baseline HAQ-DI score, corticosteroid treatment, and major advanced organ involvement were predictive of death on multivariable analysis; a 1-point increase in baseline HAQ-DI score multiplied the risk of death by 2.7 (p < 0.001) and multiple advanced major organ involvement multiplied the risk of death by 2.8 (p < 0.05). Multivariable analysis showed that baseline modified Rodnan Skin Score (mRSS) and baseline HAQ-DI score were associated with HAQ-DI score progression at 1 year (p < 0.05), but there was no association between baseline organ involvement and HAQ-DI score progression at 1 year. HAQ-DI score, major advanced organ involvement, and death were successfully used to model long-term disease progression in dcSSc.
HAQ-DI score and major advanced organ involvement were comparable predictors of mortality risk in dcSSc. Baseline mRSS and baseline HAQ-DI score were predictive of HAQ-DI score progression at 1 year, indicating a correlation between these endpoints in monitoring disease progression. It is hoped that this EUSTAR analysis may change physician perception about the importance of the HAQ-DI score in dcSSc.
弥漫性皮肤系统性硬化症(dcSSc)患者预后较差。监测主观功能和残疾指标(如健康评估问卷残疾指数[HAQ-DI])的重要性不容忽视,因为 dcSSc 对患者生活质量的影响比糖尿病或血液透析更为严重。本项欧洲硬皮病试验和研究(EUSTAR)数据库分析旨在探讨受损功能对 dcSSc 预后的重要性。主要目的是确定 1 年内死亡和 HAQ-DI 评分进展的预测因素。HAQ-DI 评分、主要晚期器官受累和死亡率也用于开发一种综合模型,以预测 dcSSc 的终生进展。
这是一项在 EUSTAR 注册的 dcSSc 患者中进行的观察性、纵向研究。通过 Cox 回归和线性回归分析分别评估死亡和 HAQ-DI 评分与基线协变量的关系。开发了一个微模拟 Markov 模型,以估计/预测患者一生中 dcSSc 的自然进展。
分析包括来自 EUSTAR 数据库的有(N=690)和无(N=4132)HAQ-DI 评分评估的 dcSSc 患者。多变量分析显示,基线 HAQ-DI 评分、皮质类固醇治疗和主要晚期器官受累是死亡的预测因素;基线 HAQ-DI 评分增加 1 分,死亡风险增加 2.7 倍(p<0.001),且多个晚期主要器官受累使死亡风险增加 2.8 倍(p<0.05)。多变量分析显示,基线改良 Rodnan 皮肤评分(mRSS)和基线 HAQ-DI 评分与 1 年时 HAQ-DI 评分进展相关(p<0.05),但基线器官受累与 1 年时 HAQ-DI 评分进展无关。HAQ-DI 评分、主要晚期器官受累和死亡可成功用于模型 dcSSc 的长期疾病进展。
HAQ-DI 评分和主要晚期器官受累是 dcSSc 死亡风险的可比预测因素。基线 mRSS 和基线 HAQ-DI 评分可预测 1 年内 HAQ-DI 评分的进展,表明这两个终点在监测疾病进展方面存在相关性。希望这项 EUSTAR 分析能改变医生对 dcSSc 中 HAQ-DI 评分重要性的认识。